Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer

NCT01136226 is registered in ClinicalTrials.gov with Chesapeake Urology Research Associates as lead sponsor.

NCT NCT01136226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01136226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer
Lead sponsor
Chesapeake Urology Research Associates
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2003
Completion date
June 30, 2009
Enrollment
42 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer